Company news

Clene Inc. news in 2022

Clene Inc.'s news releases, calls and decks from 2022, newest first.

View company

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

December 26, 2022

Clene Announces Closing of $5 Million Debt Facility from the State of Maryland

December 11, 2022

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

November 27, 2022

Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights

November 6, 2022

Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland

October 30, 2022

Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights

August 14, 2022

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

August 14, 2022

Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS

July 18, 2022

Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

July 13, 2022

Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights

May 8, 2022

Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights

March 10, 2022

Clene Nanomedicine Provides Clinical Program Update

February 13, 2022

Clene Announces New Chief Financial Officer Morgan Brown

January 31, 2022

Decks in 2022